Original ArticlePembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial
Under a Creative Commons license
open access
Key words
cutaneous squamous cell carcinoma
programmed cell death protein 1 (PD-1)
immunotherapy
pembrolizumab
Cited by (0)
© 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.